Abstract
Disasters, pandemics, and their response measures can have secondary effects on the physical and psychological health of affected populations. Identifying populations vulnerable to these effects is beneficial for promoting effective health and prevention strategies. Using health insurance receipt data from 2009 to 2020, we assessed changes in prevalence of major non-communicable diseases (NCDs), including hypertension, hyperlipidemia, diabetes, and mental disorders, among affected populations before and after the Fukushima disaster and coronavirus disease (COVID-19) outbreak in Japan. Furthermore, age and sex groups with the largest increases in prevalence after these events were identified. The participants of this study were members of the Employees’ Health Insurance scheme, including employees of companies and their dependent family members. The dataset was provided by JMDC Inc. The annual age-adjusted prevalence of each disease was used to calculate the ratio of disease prevalence before and after the events. After the Fukushima disaster, hypertension, hyperlipidemia, and diabetes generally increased over a 9-year period in Fukushima Prefecture. The increase in the prevalence rate of these three NCDs and mental disorders were the highest among females aged 40–74 years compared to males and the other age groups. The prevalence of all four diseases increased after the COVID-19 outbreak in Japan, with marked increase in males aged 0–39 years. Populations that have experienced secondary health effects such as NCDs are unique to each disaster or pandemic, and it is important to provide tailor-made public health support among populations in accordance to the type of disasters and pandemic.
Highlights
We assessed secondary health effects of Fukushima disaster and COVID-19 pandemic
Non-communicable diseases increased after the disaster and COVID-19 pandemic
The increase rates were higher among females aged 40–74 years after the disaster
The increase rates were higher among males aged 0–39 years after COVID-19 pandemic
It is important to provide tailor-made public health support among populations
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by JSPS KAKENHI grant number JP20H04354.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Osaka University Research Ethics Committee gave ethical approval for this work (approval number Ci21002).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data used in the study were provided by JMDC Inc., as described in this paper. We are unable to attach all of the raw data in this paper, because it would violate the contract; however, we have included the crude prevalence data needed to replicate the study and all data produced in the present work in the manuscript and Supplementary materials.